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three months (	  .42, P  .001). Scores for the 6, 9 and
12-month survey were (	  .451, P  .001; 	  .755, P 
.001 and 	  .183, P  .074), respectively. No signifi-
cant concordances between parental reports and bioas-
says were noted in any of the time intervals. CONCLU-
SION: This research shows a strong degree of concordance
between adolescent and parental reports of drug and al-
cohol use. It shows that there is a lesser degree of concor-
dance between both adolescent and parental reports and
urine bioassays. When evaluating the results of this re-
search one must realize that the adolescents knew they
were would be required to give urine specimens and they
also knew that their parents would be contacted to cor-
roborate their responses. It is possible that such knowl-
edge may yield more valid reporting. These findings sug-
gest that outcomes data is best collected by querying
adolescents and their parents while subjecting the adoles-
cents to random drug urine bioassays. It also suggests
that the urine bioassays are far from being a gold stan-
dard. Considering the high cost of urine bioassays, less
frequent screens may be warranted if their primary effect
is that of increasing the reliability of reports. Measuring
the outcomes of substance abuse treatment services
hinges on researcher’s ability to measure post treatment
drug and alcohol use. Since alcohol and drug use are ille-
gal and socially stigmatized behaviors accurately measur-
ing their prevalence is difficult. This research suggests
that outcome measurement data should be triangulated—
that is, several different methods of data collection
should be used to assess drug and alcohol use—giving
first preference to the self reports of the adolescents, and
then using parental reports when the adolescent is unable
or unwilling to participate and using infrequent but ran-
dom urine bioassays to increase the reliability of the self-
reports.
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OBJECTIVE: to assess medical costs of dementia for pa-
tient (P) and health system (HS) and identify determi-
nants of high costs. METHODS: Study population 
605 subjects  65 years: two referent cohorts of 106 sub-
jects without cognitive impairment and 113 subjects with
cognitive impairment but no dementia and one cohort of
386 patients with mild (MMSE  21, n  83), moderate/
mild (MMSE 15–20, n  108), moderate (MMSE 10–14,
n  62) or severe (MMSE  10, n  133) dementia.
Medical costs were calculated using retrospective data
covering the last 12 months and included visits from GPs
and to specialists, physiotherapy, nursing, hospitaliza-
tions, medications, material for incontinence. For de-
mented patients, costs were calculated according to place
of living (community, n  218; institution, n  168). To-
tal costs and costs for HS and P were expressed as mean
monthly costs. Multivariate covariance analysis was used
to test the effect of dementia on medical costs controlling
for other cost determinants. RESULTS: Total costs: the
highest costs were for demented patients in institution,
with an increase according to severity (17,077, 45,433,
44,082 and 61,667 Bef in the four subcohorts). The main
cost components were nursing and hospitalizations. Costs
for P: the highest costs were incurred for severely de-
mented patients at home or in institution (5464 and 4191
Bef respectively), the main component being medications.
Costs for HS: the highest costs were for demented pa-
tients in institution: 57,476 Bef for severe, 41,525 and
40,769 Bef for moderate/mild and moderate, 13,541 Bef
for mild cases. By comparison costs for severely de-
mented at home amounted to 14,165 Bef. In covariance
analysis, dementia increased medical costs by 44% in
comparison to referent subjects (95% CI: 18%–75%) af-
ter adjusting for age, VIPO status and co-morbidity. The
increase was proportional to severity. Results of prospec-
tive data collection will be presented; implications will be
discussed.
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OBJECTIVES: This analysis was conducted to examine
the principal cost drivers for patient care within the Na-
tional Outcomes Measurement Study in Schizophrenia, a
longitudinal, observational study of the clinical, human-
istic, and economic outcomes of Canadian schizophrenia
patients. METHODS: To date, 376 patients have been
recruited from 32 academic and community sites across
Canada. Inpatient (hospitalizations) and outpatient (health
professional visits, counseling, legal costs, employment
status) resource use (RU) is collected monthly from all
patients. Physician-reported RU includes psychiatric medi-
cations. Mean costs of care per patient-month were estab-
lished during the first three months after registration, and
regression models measured the predictive power of base-
line demographic and clinical parameters. RESULTS: At
registration, 67% of the study patients were male, 90%
Caucasian, 41  11 years with an average age of onset of
psychotic symptoms of 23  7 years and an average du-
ration of symptoms of 17  11 years. Seventy percent
had a Clinical Global Impression score of “mild to mod-
erately ill”; 72% had a CGImprovement score of at least
“minimally improved” and the mean SOFAS score was
60  13. Based on 364 patients with at least 2 m of RU
data, the average total cost was $CDN 3441 per patient-
month, ($772: pharmaceuticals, $1430: inpatient care,
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$1239: outpatient care). Though the overall predictive
power of the model was low (R2  0.10), the most sig-
nificant predictors of increased total cost were: CGIm-
pression (P  .001), SOFAS (P  .014), ethnicity (P 
.001), and onset age (P  .080). CONCLUSIONS: Inpa-
tient care represents the largest component (42%) of the
total cost of care for patients in this study. Costs are
higher for Caucasian patients, patients with later onset of
disease, and patients with more severe disease measured
by CGImpressions and SOFAS. Whether the use of more
effective medications will decrease hospitalization and to-
tal costs remains to be determined.
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Complete economic evaluations of new antidepressants
should consider the impact of depression on productivity
costs associated with impaired work performance and
other disability as well as on direct medical costs. OB-
JECTIVES: This study compares costs and effectiveness
of reboxetine and fluoxetine for treating major depres-
sion, focusing on the productivity improvements associ-
ated with each treatment. METHODS: A semi-Markov
model was constructed describing the course of depres-
sion and its treatment. The model combines efficacy data
from two head-to-head clinical trials of reboxetine and
fluoxetine with resource use estimates from expert opin-
ion elicited by questionnaire. Unit costs for resources
were obtained from the medical literature. The number
of disability days associated with each health state in the
model was estimated from population surveys and clini-
cal trial information. The model generated cost-effective-
ness measures for the total population as well as the sub-
set of severe patients (defined as patients with baseline
Clinical Global Impression severity scores of “markedly
ill”, “severely ill”, or “among the most extremely ill”) found
in the clinical trials. RESULTS: Model results showed no
significant differences in effectiveness between the two
treatment groups. For the total population, annual direct
medical and productivity costs totaled $6679 for rebox-
etine and $6958 for fluoxetine. Among severe patients,
total costs were $6946 for reboxetine and $7491 for flu-
oxetine. Productivity costs accounted for approximately
50% of the total cost of depression in both treatment
groups and patient populations. Sensitivity analyses con-
firmed the model’s robustness. CONCLUSIONS: The model
shows reboxetine to be cost saving compared to fluoxet-
ine for the treatment of major depression. The majority
of savings results from improvements in patient produc-
tivity, with the greatest potential for savings found in the
severe patient population. 
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OBJECTIVE: To compare the costs and quality of life of
77 patients who relapse with a control group of 68 non-
relapse patients, in schizophrenia. METHODS: Patients
were selected from current (active) psychiatric caseloads
drawn from urban, suburban and rural Leicester and Leices-
tershire. Relapse cases were identified by the re-emer-
gence and aggravation of symptoms, and by psychiatric
in-patient re-admissions, current or within the last 6 months.
Data collection included: social and demographic pro-
files, DSM IV classification, PANSS, CGI, GAF, Quality
of Life (Lehman), EuroQol, and health care utilization.
Standard parametric/non-parametric tests are used to test
for differences in outcomes and costs for relapse and
non-relapsing patients. Hypothesis-driven analyses focus
on the correlates of quality of life, links between symp-
toms and functioning, socio-economic consequences of
schizophrenia, and cost consequences of positive symp-
toms and functioning deficits. Standard multivariate analysis
will identify key determinants of costs, and Generalized
Linear Models will be used to predict relapse status. Pro-
visional results confirm higher costs and lower quality of
life for patients who relapse. CONCLUSIONS: Schizo-
phrenia is a long-term, debilitating and costly illness. Po-
tentially high costs are incurred by health care providers,
social services and other care agencies, and by families
and sufferers themselves. One of the most costly aspects
of schizophrenia is associated with illness relapse, which
has been estimated, for example, to cost $2 billion in re-
admission costs in the US. There is currently no equiva-
lent estimate for the UK. The findings from this study
will be of interest to policy-makers who face difficult eco-
nomic choices concerning new but more expensive drug
treatments for patients with schizophrenia. The challenge
for new antipyschotic treatments is to improve efficacy
and compliance and thereby reduce relapse rates. In turn
this would be expected to bring about reductions in the
total national costs of schizophrenia, whilst also improv-
ing the welfare of patients.
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OBJECTIVE: To assess utilization patterns, frequency of
side effects, and the cost of side effects associated with
